During the past decade, Neurogenetics, NYU at Rivergate conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Neurogenetics, NYU at Rivergate" are "Gaucher Disease" (3 trials). Many other conditions were trialed in "Neurogenetics, NYU at Rivergate" in a lesser frequency.

Most popular intervention types in "Neurogenetics, NYU at Rivergate" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Taliglucerase alfa" (2 trials) and "Plant cell expressed recombinant glucocerebrosidase (prGCD)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Neurogenetics, NYU at Rivergate" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Neurogenetics, NYU at Rivergate". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Neurogenetics, NYU at Rivergate, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Neurogenetics, NYU at Rivergate, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".